| This week's sponsor is Medidata. | | | Whitepaper | Combining the Discipline of Clinical R&D with the Promise of mHealth
Biosensors, wearables and apps are redefining clinical R&D by providing real-time insights into patient care. Explore the opportunities, challenges and value of data science in mHealth. Discover more. Download Today |
| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. | |
|
Top Stories Of The Week Monday, December 5, 2016 Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early next year with the FDA, but rival Kite Pharma is hot on its heels as it starts a rolling submission with the regulator. Wednesday, December 7, 2016 If President-elect Donald Trump is to “reform” the FDA as promised, he might start with an outsider pick for commissioner. According to Bloomberg’s sources, the incoming administration is considering one that's far outside the usual box in tech capitalist Jim O’Neill. Wednesday, December 7, 2016 AbbVie missed its survival targets in a new midstage trial of its PARP breast cancer candidate veliparib in combo with chemo, but the company is still hopeful its med can win out in an ongoing, larger late-stage study. Monday, December 5, 2016 At the ASH meeting in San Diego, Kite Pharma and Novartis presented impressive data on their chimeric antigen receptor T-cell (CAR-T) therapies to treat blood cancers, and both appear to be on track to file for FDA approval soon. But concerns about toxic side effects continue to dog this emerging form of immunotherapy. Now a set of researchers at the Fred Hutchinson Cancer Research Center in Seattle who are partially funded by Juno are investigating methods for fine-tuning CAR-T treatments—and they presented early signs of success. Thursday, December 1, 2016 Vaccines are causing more autism cases among kids? Frontiers in Public Health recently accepted a survey-based research effort—decidedly unscientific in design—suggesting it's so. Now, after receiving heavy criticism, the publisher has retracted the abstract. Monday, December 5, 2016 Teleflex has inked a deal to acquire Vascular Solutions for $1 billion, picking up devices for minimally invasive coronary and peripheral vascular procedures and gaining entry into those markets. Friday, December 2, 2016 Eli Lilly’s aggressive Taltz DTC advertising seems to be giving the new-to-market drug a boost in the next-generation psoriasis drug battle against Novartis' Cosentyx. While analyst Lynn Price was careful to note that Taltz and Cosentyx market share should eventually stabilize, a new report from her firm Spherix Global Insights indicates the Taltz DTC campaign is having an early impact on uptake of the drug. Monday, December 5, 2016 Charles River Laboratories has launched CRISPR/Cas9 services through a licensing deal with the Broad Institute, as a dispute over ownership of the gene-editing technology gathers pace. Monday, December 5, 2016 Sanofi is jumping into the Rituxan biosimilars fray in a potential $200 million-plus deal with JHL Biotech, putting the Taiwan-based drugmaker's new China biologics plant into action. Resources Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. |
